An experimental drug regimen under development by AbbVie could change the way hepatitis C is treated, according to a special designation it received from the Food and Drug Administration.

Kadmon Pharmaceuticals earlier this month announced that it has launched a new 600 mg/day dose pack of Ribasphere RibaPak (ribavirin, USP), Kadmon's proprietary ribavirin regimen available in a daily, two-pill compliance package for enhanced therapy adherence.

A phrase like “silent killer” sounds creepy enough on its own, but it’s an often-used one for a virus that, according to the Centers for Disease Control and Prevention, infects 1.3% to 1.9% of people in the United States.


The Food and Drug Administration has approved a treatment for hepatitis C made by Vertex Pharmaceuticals, the agency said Monday.

Medication adherence among hepatitis C patients may improve when patients take antidepressants, according to a new analysis by pharmacy benefit manager Medco Health Solutions presented Monday at the International Conference on Viral Hepatitis.

Drug makers Valeant Pharmaceuticals International and Kadmon Pharmaceuticals will collaborate to develop antiviral drugs for...

An investigational drug in late-stage clinical trials increased the cure rate in patients with hepatitis...